Covista Inc.
CVSA
$115.82
-12.33%
Covista Inc. is an American healthcare educator serving over 97,000 students across five accredited institutions, addressing the U.S. healthcare workforce shortage through personalized, tech-enabled education. As a scaled operator in the for-profit education sector, it holds a distinct position by focusing exclusively on healthcare training, a field with structural demand tailwinds. The current investor narrative centers on the company's ability to sustain enrollment growth and margin expansion amid regulatory scrutiny and competitive pressures, with recent quarterly results showing steady revenue growth and robust profitability.…
CVSA
Covista Inc.
$115.82
Investment Opinion: Should I buy CVSA Today?
Rating: Buy. CVSA is a compelling value play in the healthcare education space, with a forward P/E of 13.0x and PEG of 0.25x, supported by consistent revenue growth and strong cash flows. The analyst consensus is bullish, with an average target of $156.25 implying 34.9% upside. Supporting evidence includes: (1) trailing P/E of 20.3x is below the 5-year average of ~25x; (2) revenue growth of 4.5% YoY with TTM revenue of $1.91B; (3) robust free cash flow of $336.28M TTM; and (4) a PEG ratio of 0.25x, indicating undervaluation relative to growth. The primary risks are margin compression (net margin down to 8.5%) and growth deceleration. This Buy rating would downgrade to Hold if revenue growth falls below 3% or net margin drops below 7%, and upgrade to Strong Buy if growth re-accelerates above 6% and margins stabilize. Overall, CVSA appears undervalued relative to its history and growth prospects, offering a favorable risk/reward at current levels.
Sign up to view all
CVSA 12-Month Price Forecast
CVSA presents a compelling value opportunity with a low forward P/E and PEG ratio, supported by consistent revenue growth and strong cash flows. The stock's downtrend and margin compression are concerns, but the valuation already discounts these risks. The base case of 4-5% growth and stable margins supports a target of $156.25, offering 34.9% upside. The bull case requires growth re-acceleration, while the bear case hinges on further deceleration or regulatory shocks. Given the attractive valuation and analyst support, the stance is bullish with medium confidence. An upgrade to high confidence would require evidence of margin stabilization and growth re-acceleration in the next quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Covista Inc.'s 12-month outlook, with a consensus price target around $156.25 and implied upside of +34.9% versus the current price.
Average Target
$156.25
0 analysts
Implied Upside
+34.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $175
Analyst target range
Four analysts cover CVSA, with a consensus recommendation leaning bullish (all recent ratings are Outperform or Buy). The average target price is $156.25, implying 34.9% upside from the current price of $115.82. The high target of $175.00 suggests 51.1% upside, while the low target of $140.00 implies 20.9% upside. The consensus is clearly bullish, with no Hold or Sell ratings in the data. The target range is relatively tight (low to high spread of $35, or 22% of the average), indicating reasonable conviction among analysts. The high target likely assumes continued enrollment growth, margin expansion, and potential multiple re-rating, while the low target may factor in regulatory risks or competitive pressures. Recent institutional ratings show consistent upgrades or reaffirmations: Barrington Research has maintained an Outperform rating since October 2025, and Truist Securities reiterated a Buy in May 2026. This pattern of sustained positive ratings reinforces the bullish consensus. The implied upside of 34.9% is significant, but investors should consider that analyst targets often embed optimistic assumptions and may not be achieved if headwinds materialize.
Bulls vs Bears: CVSA Investment Factors
CVSA presents a mixed picture: strong fundamentals with consistent revenue growth, solid profitability, and a bullish analyst consensus, but offset by decelerating growth, margin compression, and a stock in a downtrend. The bull case rests on the company's structural tailwinds in healthcare education and attractive valuation (PEG 0.25x, forward P/E 13.0x), while the bear case highlights slowing momentum and near-term margin pressures. Currently, the evidence slightly favors the bull side due to the significant upside to analyst targets (34.9%) and low valuation, but the key tension is whether revenue growth can re-accelerate and margins stabilize. If growth continues to decelerate, the stock could remain range-bound or test support near the 52-week low of $86.97.
Bullish
- Strong Revenue Growth Trajectory: Revenue grew 4.5% YoY to $487.03M in Q3 2026, with consistent sequential growth from $457.11M (Q4 2025) to $503.39M (Q2 2026). This demonstrates sustained demand for healthcare education, supported by structural workforce shortages.
- Attractive Valuation with PEG of 0.25x: The trailing PEG ratio of 0.25x indicates the stock is cheap relative to its earnings growth rate. Combined with a forward P/E of 13.0x, the market appears to be discounting near-term risks, offering potential upside if growth continues.
- Analyst Consensus Bullish with 34.9% Upside: All four analysts rate CVSA as Outperform/Buy, with an average target of $156.25 (34.9% upside) and a high target of $175.00 (51.1% upside). This strong consensus reflects confidence in the company's fundamentals and growth prospects.
- Robust Profitability and Cash Flow: Net margin of 8.5% and operating margin of 18.9% in Q3 2026 demonstrate solid profitability. Trailing twelve-month free cash flow of $336.28M provides ample liquidity for reinvestment and share buybacks ($67.5M in Q3 2026).
Bearish
- Revenue Growth Deceleration: YoY revenue growth slowed from 6.6% in Q2 2026 to 4.5% in Q3 2026. If this trend continues, it could signal market saturation or increased competition, undermining the growth thesis and justifying the low forward P/E.
- Net Margin Compression: Net margin dropped sharply from 15.2% in Q2 2026 to 8.5% in Q3 2026, a decline of 670 basis points. This raises concerns about cost control and pricing power, potentially indicating rising operating expenses or competitive pressures.
- Stock in Broad Downtrend, Underperforming Market: CVSA is down 16.29% over the past year and trades at 74.1% of its 52-week range. It has underperformed the S&P 500 by 6.45% over 3 months and 2.16% over 1 month, signaling relative weakness and lack of catalyst-driven buying.
- Liquidity Concerns with Current Ratio of 0.82: A current ratio below 1.0 indicates potential short-term liquidity pressure, as current liabilities exceed current assets. While operating cash flow is strong, this metric warrants monitoring for any deterioration in working capital management.
CVSA Technical Analysis
The stock is in a broad downtrend, with a 1-year price change of -16.29% and currently trading at 74.1% of its 52-week range (current price $115.82 vs. 52-week low $86.97 and high $156.26). This positioning near the lower end of the range suggests bearish sentiment, though the stock is off the lows, indicating potential value interest but not yet a confirmed reversal. The 52-week high of $156.26 represents a key resistance level, while the low of $86.97 serves as support. With a beta of 0.616, the stock is less volatile than the market, meaning it may underperform in rallies but also offer relative downside protection. Short-term momentum is mixed: the 1-month price change is -1.56%, while the 3-month change is -0.16%, both underperforming the S&P 500's gains of 0.6% and 6.29%, respectively. This divergence—where the stock is flat to slightly down while the market rallies—signals relative weakness and a lack of catalyst-driven buying. The recent price action shows a sharp drop from $133.18 on July 13 to $115.82 on July 15, a 13% decline in two days, suggesting a potential breakdown or profit-taking after a prior rally. The 52-week low of $86.97 provides a clear support level; a break below would signal a continuation of the downtrend, while a move above the 52-week high of $156.26 would indicate a bullish reversal. Given the low beta, the stock's volatility is muted relative to the market, which may appeal to risk-averse investors but also limits upside participation in strong market rallies.
Beta
0.62
0.62x market volatility
Max Drawdown
-14.6%
Largest decline past year
52-Week Range
$87-$156
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CVSA Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +0.6% |
| 3m | -0.2% | +6.3% |
| 6m | — | +9.1% |
| 1y | — | +20.9% |
| ytd | — | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVSA Fundamental Analysis
Revenue has shown consistent growth, with the most recent quarter (Q3 2026) reporting $487.03 million, up 4.5% year-over-year from $466.06 million in the prior-year quarter. The trailing twelve-month revenue trend is positive, with sequential growth from $457.11 million (Q4 2025) to $462.29 million (Q1 2026) to $503.39 million (Q2 2026) and then $487.03 million (Q3 2026). The YoY growth rate has decelerated from 6.6% in Q2 2026 to 4.5% in Q3 2026, but the company continues to expand its top line, driven by strong enrollment in healthcare programs. The revenue trajectory supports the investment case of a growing addressable market, though deceleration warrants monitoring for competitive or regulatory headwinds. Profitability is solid: net income for Q3 2026 was $41.64 million, with a net margin of 8.5%, down from 15.2% in Q2 2026 but still healthy. Gross margin remains stable at 56.7%, consistent with the prior year's 57.1%, indicating pricing power and cost control. Operating margin was 18.9% in Q3 2026, slightly below the 22.1% in Q2 2026 but above the 19.4% in the year-ago quarter. The company is profitable and generates strong cash flows, with trailing twelve-month free cash flow of $336.28 million. The balance sheet is moderately leveraged: debt-to-equity is 0.54, and the current ratio of 0.82 suggests some liquidity pressure, but operating cash flow of $186.17 million in Q3 2026 easily covers interest expenses (interest coverage ratio of 6.8x). Return on equity (ROE) is 16.2%, reflecting efficient capital use. The company does not pay a dividend, instead reinvesting in growth and share buybacks (evidenced by $67.5 million in stock repurchases in Q3 2026). Overall, financial health is strong, with ample cash generation to fund operations and growth.
Quarterly Revenue
$487030000.0B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
56.7%
Latest Quarter
Free Cash Flow
$336279000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVSA Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 20.3x, while the forward P/E is 13.0x, implying the market expects earnings growth. The gap between trailing and forward P/E suggests a significant earnings ramp is priced in, consistent with analyst estimates of $11.04 EPS for the current fiscal year. Compared to the industry average (not provided, but the sector is Consumer Cyclical/Personal Products & Services), the stock's P/E of 20.3x appears reasonable given its growth and margins. The PEG ratio of 0.25x (based on trailing earnings) indicates the stock is cheap relative to its growth rate, though this metric should be used cautiously. Historically, the stock's trailing P/E has ranged from a low of 8.9x (Q3 2023) to a high of 104.4x (Q1 2023), with the current 20.3x near the middle of that range. The current P/E is below the 5-year average (approximately 25x based on historical data), suggesting the stock is not overvalued relative to its own history. The forward P/E of 13.0x is near the lower end of historical valuations, implying the market may be discounting near-term risks or that earnings growth is not fully appreciated.
PE
20.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~23x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CVSA's primary financial risk is margin compression, as net margin fell from 15.2% in Q2 2026 to 8.5% in Q3 2026, a 670 bps decline. While gross margin remains stable at 56.7%, operating margin also slipped from 22.1% to 18.9%, indicating rising costs. The current ratio of 0.82 suggests potential liquidity strain, though strong operating cash flow of $186.17M in Q3 2026 and interest coverage of 6.8x mitigate near-term solvency risk. Revenue growth deceleration from 6.6% to 4.5% YoY is another concern, as it may signal market saturation or competitive pressures. Market & Competitive Risks: The stock's beta of 0.616 implies lower market correlation, but its 1-year price decline of 16.29% versus the S&P 500's gain of 20.92% highlights significant relative underperformance. The for-profit education sector is subject to regulatory changes, which could impose new compliance costs or restrict enrollment. Competition from other healthcare educators and online platforms could pressure pricing and enrollment growth. The stock's position near the lower end of its 52-week range (74.1%) suggests bearish sentiment, and the recent 13% drop over two days (July 13-15) indicates potential profit-taking or a breakdown. Worst-Case Scenario: A combination of continued revenue deceleration, margin erosion, and adverse regulatory action could drive the stock to its 52-week low of $86.97, representing a 24.9% decline from the current price of $115.82. In a severe downturn, the stock could test historical support levels, potentially falling to $80 or lower, implying a loss of up to 31% from current levels. The low beta offers some cushion, but the stock's downtrend and weak relative strength amplify downside risk.
FAQ
The key risks are: (1) Financial risk: net margin compression from 15.2% to 8.5% in one quarter, which could persist if costs continue to rise; (2) Growth risk: revenue growth decelerated from 6.6% to 4.5% YoY, and further slowing could pressure the stock; (3) Regulatory risk: the for-profit education sector is subject to government scrutiny, which could impact enrollment or impose new costs; (4) Market risk: the stock is in a downtrend, down 16.29% over the past year, and has underperformed the S&P 500 by 6.45% over 3 months. The most severe risk is a combination of these factors driving the stock to its 52-week low of $86.97, a potential 24.9% decline from current levels.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock reaching the analyst average target of $156.25, driven by steady 4-5% revenue growth and stable margins. The bull case (30% probability) targets $175.00, assuming growth re-acceleration and multiple expansion. The bear case (20% probability) sees the stock falling to $86.97 if growth decelerates below 3% or margins deteriorate. The most likely scenario is the base case, supported by the company's strong cash flows and low valuation. Key assumptions include enrollment growth of 3-4% and operating margins near 19%.
CVSA appears undervalued based on multiple metrics. The trailing P/E of 20.3x is below the 5-year average of approximately 25x, and the forward P/E of 13.0x suggests the market expects significant earnings growth. The PEG ratio of 0.25x (trailing) is well below 1.0, indicating the stock is cheap relative to its earnings growth. Compared to the broader market, the P/E is reasonable given the company's net margin of 8.5% and ROE of 16.2%. The valuation implies the market is discounting risks such as growth deceleration and regulatory headwinds, but if the company delivers on earnings estimates ($11.04 EPS), the stock offers substantial upside.
CVSA appears to be a good buy for value-oriented investors with a medium-term horizon. The stock trades at a forward P/E of 13.0x, well below its 5-year average of ~25x, and has a PEG ratio of 0.25x, indicating it is cheap relative to its growth rate. Analyst consensus is bullish, with an average target of $156.25 implying 34.9% upside. However, risks include margin compression (net margin fell to 8.5% in Q3 2026 from 15.2% in Q2) and revenue growth deceleration (4.5% YoY vs. 6.6% prior). For investors willing to tolerate near-term volatility, the current price offers a compelling entry point, but those seeking immediate catalysts may prefer to wait for confirmation of margin stabilization.
CVSA is better suited for long-term investment due to its low beta (0.616), consistent revenue growth, and attractive valuation. The stock's downtrend and recent volatility make it less ideal for short-term trading, as near-term catalysts are uncertain. With a forward P/E of 13.0x and a PEG of 0.25x, the stock offers value that may take time to be recognized. A minimum holding period of 12-18 months is recommended to allow for earnings growth and potential multiple expansion. The company does not pay a dividend, so total return depends on price appreciation. Long-term investors benefit from the structural demand for healthcare education and the company's strong cash flows.